Premium
Trends in Opioid use for Chronic Neuropathic Pain: a Survey of Patients Pursuing Enrollment in Clinical Trials
Author(s) -
Gilron I,
Bailey JM
Publication year - 2003
Publication title -
journal of the peripheral nervous system
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1
H-Index - 67
eISSN - 1529-8027
pISSN - 1085-9489
DOI - 10.1046/j.1529-8027.2003.03016_18.x
Subject(s) - postherpetic neuralgia , medicine , neuropathic pain , opioid , adverse effect , addiction , dosing , pain ladder , clinical trial , chronic pain , anesthesia , neuralgia , tricyclic , physical therapy , psychiatry , pharmacology , receptor
PURPOSE: Clinical trials suggest that opioids relieve neuropathic pain and decrease pain‐related disability. We conducted a pilot study of current prescribing trends and patients’ attitudes towards opioids for neuropathic pain. METHODS: A patient questionnaire was completed by individuals pursuing enrollment in neuropathic pain clinical trials at our facility. RESULTS: Of 154 patients with diabetic neuropathy (55.2%), postherpetic neuralgia (29.9%), idiopathic peripheral neuropathy (9.7%) and other neuropathies (5.2%), 73.4% complained of inadequate pain control, the mean pain duration was 4.7 (SD = 4.4) yr and the mean pain intensity (0–10) was 7.7 (SD = 2.3). In this group, 40.9% had never tried opioids and 24.7% had never tried any opioids, tricyclic antidepressants or anticonvulsants. Only 9.7% were receiving long‐acting opioids or “around the clock” dosing whereas 25.3% were receiving opioids on an “as needed” basis. Opioids combined with tricyclic antidepressants and/or anticonvulsants were used in 11.0%. Fear of addiction and adverse effects were expressed by 31.8% and 46.8% respectively. CONCLUSION: These data suggest that barriers to opioid therapy for neuropathic pain include patients’, and possibly physicians’, fears of addiction and adverse effects, which are exaggerated in light of current evidence. The merits of continuous treatment with sustained‐release opioids, “as needed” dosing with short‐acting preparations, or combining opioids with other agents are discussed, Continued research and communication between health professionals, law enforcement officials and legislators is vital in order to facilitate appropriate opioid use which has a minimal negative impact on the public yet optimally benefits individuals who suffer from disabling neuropathic pain.